Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of the Real-life Management of Psoriasis Patients Treated With Otezla (Apremilast) in Belgium

Trial Profile

An Observational Study of the Real-life Management of Psoriasis Patients Treated With Otezla (Apremilast) in Belgium

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms OTELO
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2018.
    • 04 Oct 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Dec 2018.
    • 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top